Standout Papers

Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subj... 1998 2026 2007 2016 5.0k
  1. Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction (1998)
    Steven M. Haffner, Seppo Lehto et al. New England Journal of Medicine
  2. Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α (2006)
    Marie Lagouge, Carmen Argmann et al. Cell
  3. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial (2005)
    R. John Simes, Philip J. Barter et al. The Lancet
  4. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial (2002)
    Jean‐Louis Chiasson, Robert G. Josse et al. The Lancet
  5. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial (2006)
    Hertzel C. Gerstein, Salim Yusuf et al. The Lancet
  6. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance (2003)
    Jean‐Louis Chiasson, Robert G. Josse et al. JAMA
  7. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity (1998)
    Samir S. Deeb, Lluís Fajas et al. Nature Genetics
  8. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. (1990)
    Markku Laakso, Steven V. Edelman et al. Journal of Clinical Investigation
  9. Diabetes and atherosclerosis: An epidemiologic view (1987)
    Kalevi Pyörälà, Markku Laakso et al. Diabetes/Metabolism Reviews
  10. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity (2005)
    K. Malmberg, Lars Rydén et al. European Heart Journal
  11. How Good a Marker Is Insulin Level for Insulin Resistance? (1993)
    Markku Laakso American Journal of Epidemiology
  12. Hyperglycemia and cardiovascular disease in type 2 diabetes. (1999)
    Markku Laakso Diabetes
  13. Insulin resistance and hyperglycaemia in cardiovascular disease development (2014)
    Markku Laakso, Johanna Kuusisto Nature Reviews Endocrinology
  14. Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis (2018)
    Miriam S. Udler, Jaegil Kim et al. PLoS Medicine

Immediate Impact

24 from Science/Nature 161 standout
Sub-graph 1 of 17

Citing Papers

A brief history of human disease genetics
2020 StandoutNature
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
2019 Standout
2 intermediate papers

Works of Markku Laakso being referenced

Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
2018 Standout
Decreased plasma β‐amyloid in the Alzheimer's disease APPA673T variant carriers
2017
and 3 more

Author Peers

Author Last Decade Papers Cites
Markku Laakso 22794 15999 13178 667 56.6k
Gerald M. Reaven 29768 13376 18678 663 58.0k
Ele Ferrannini 28308 14917 11541 523 50.0k
Steven M. Haffner 32314 10990 11063 517 60.5k
Takashi Kadowaki 13603 24742 16009 858 60.5k
Marja‐Riitta Taskinen 23571 8529 6389 565 44.3k
Steven E. Kahn 20367 12423 13019 467 45.2k
Iichiro Shimomura 10688 15624 18836 659 55.0k
Ralph A. DeFronzo 23648 20450 17277 411 50.5k
Ronald M. Krauss 17976 7694 9541 378 47.3k
Hertzel C. Gerstein 25805 8604 7401 496 49.6k

All Works

Loading papers...

Rankless by CCL
2026